Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05017935 · ClinicalTrials.gov registry record · NA

RADIANCE Continued Access Protocol

A NA study of Hypertension and Cardiovascular Diseases, sponsored by ReCor Medical.

Active
Registry status
NA
Development phase
300
Enrollment target
20
Study locations

NCT05017935: Active NA study of Hypertension and Cardiovascular Diseases, sponsored by ReCor Medical.

NCT05017935 is a NA study of Hypertension and Cardiovascular Diseases that is active but no longer recruiting, run by ReCor Medical. The registered enrollment target is 300 participants, below the 3,507-participant average among 470 other Hypertension trials with a reported enrollment target (91% lower). The trial reports 20 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05017935, a NA study of Hypertension and Cardiovascular Diseases, is active but no longer recruiting, sponsored by ReCor Medical.

ACTIVE NOT RECRUITING
Registry status
NA
Development phase
300 participants
Enrollment target
20
Study locations

Study Summary

RADIANCE CAP is a non-randomized study designed to allow for continued access to ultrasound renal denervation therapy via the Paradise System, and to allow for the on-going collection of safety and effectiveness data in subjects with uncontrolled hypertension despite the prescription of antihypertensive medications.

Interventions

  • DEVICE Renal Denervation

Study Locations (20)

California

  • Cardiovascular Institute of San Diego - Chula Vista
  • Cedars-Sinai Medical Center - Los Angeles
  • Sutter Health - Sacramento
  • Pacific Heart Institute - Santa Monica

Florida

  • The Cardiac and Vascular Institute - Gainesville
  • Baptist Hospital of Miami - Miami
  • Orlando Health - Orlando

Illinois

  • Northwestern University - Chicago
  • Prairie Education and Research Cooperative - Springfield
  • SIU Medicine - Springfield

Massachusetts

  • Boston Medical Center - Boston
  • The Brigham and Women's Hospital - Boston
  • UMASS Memorial Medical Center - Worcester

Maryland

  • Lifebridge Health - Baltimore
  • Tidal Health - Salisbury

Connecticut

  • Bridgeport Hospital - Bridgeport

Georgia

  • Emory - Atlanta

Indiana

  • Parkview Research Center - Fort Wayne

Trial Details

FieldValue
Enrollment Target 300 participants
Start Date 2022-05-04
Est. Completion 2028-12-31
Phase NA
ReCor Medical

5 total trials

What the registry record for NCT05017935 still lists

NCT05017935 is an interventional study that assigns participants to a tested intervention. The registered 300 participants enrollment target is mid-sized for trials with a published cap, below the 3,507-participant average among 470 other Hypertension trials with a reported enrollment target (91% lower).

The record links to 4 conditions, with Hypertension appearing as the primary indexed condition, and to 1 intervention - of which Renal Denervation is the first listed.

NCT05017935 names 20 study sites across 10 states, led by California, Florida, Illinois.

Frequently Asked Questions

What is clinical trial NCT05017935 about?

NCT05017935 is a clinical study titled "RADIANCE Continued Access Protocol". RADIANCE CAP is a non-randomized study designed to allow for continued access to ultrasound renal denervation therapy via the Paradise System, and to allow for the on-going collection of safety and effectiveness data in subjects with uncontrolled hypertension despite the prescription of antihyperten...

What is the current status of trial NCT05017935?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 300 participants. The study started on 2022-05-04. Estimated completion is 2028-12-31.

What conditions does trial NCT05017935 study?

This clinical trial studies the following conditions: Hypertension, Cardiovascular Diseases, Vascular Diseases, Hypertension, Resistant to Conventional Therapy.

What interventions are being tested in trial NCT05017935?

The interventions under investigation include: Renal Denervation (DEVICE).

Who is sponsoring clinical trial NCT05017935?

This trial is sponsored by ReCor Medical, which has 5 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05017935 being conducted?

This trial has 20 study locations across California, Connecticut, Florida, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Hypertension

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05017935's enrollment target sits among peer trials

300 170th of 470 higher than 291 of 470 other Hypertension trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Hypertension trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00353483 · 300 participants

    Effect of Neoadjuvant or Adjuvant Systemic Therapy on Breast Cancers, Bone Marrow Cancer Cells, and Circulating Cancer Cells

  • NCT00588185 · 300 participants · NA

    [18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone Pet Imaging in Patients With Progressive Prostate Cancer

  • NCT00682032 · 300 participants · NA

    The Effect of Beta-glucan in Non-Small Cell Lung Cancer

  • NCT00870064 · 300 participants · NA

    The Treatment of Type I Open Fractures in Pediatrics

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05017935, the US trial registry maintained by the National Library of Medicine. NCT05017935 (mid enrollment · wide site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.